Titan Medical (NASDAQ:TMDI) has surged ~25.7% after Oppenheimer initiated its coverage with an outperform rating and the price target of $4.00 per share implies ~123.5% upside to the previous close. The analyst calls Titan Medical an ‘attractive micro-cap play’ with the company’s collaboration with Medtronic underlying the thesis.
"The Investors's Chief Problem--and even his worst enemy--is likely to be himself" ---Benjamin Graham